008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. (23rd August 2021)

• Record Type: Journal Article
• Authors: Roos, Izanne; Malpas, Charles B; Leray, Emmanuelle; Buzzard, Katherine; Skibina, Olga; Lechner-Scott, Jeannette; McCombe, Pamela; Slee, Mark; Butler, Ernest; Macdonell, Richard; Walt, Anneke van der; Hodgkinson, Suzanne; Barnett, Michael; Vucic, Steve; Vukusic, Sandra; Butzkueven, Helmut; Kalincik, Tomas
• Is Part Of: BMJ neurology open. Volume 3(2021) Supplement 1
• Page Start: A4
• Page End: A4
• Publication Date: 2021-08-23
• Subjects: Neurology -- Periodicals; 616.8
• DOI: 10.1136/bmjno-2021-ANZAN.8
• Languages: English
• ISSNs: 2632-6140

Abstract

Abstract : Objectives: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. Methods: This was a retrospective cohort study from two large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12-months were included in the analysis. The primary study outcome was annualised relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. Results: 18 029 eligible treatment discontinuation epochs were identified for seven therapies. Rates of relapse started to increase 2-months after natalizumab cessation. Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation. After discontinuation of fingolimod, rates of relapse increased overall, and stabilised faster in patients who started a new therapy within 1-2 months. Magnitude of disease reactivation for other therapies was low, but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were higher relapse rate in the year before cessation, female sex, younger age and higher EDSS. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). Conclusion: Understanding the rate of disease reactivation after discontinuing different MS immunotherapies will help guide optimal wash-out times for therapeutic agents during treatment sequencing.